Drew joined Pappas Capital in January 2020 as a Venture Fellow where he participated actively in investment opportunity evaluation, due diligence and deal flow management. Prior to joining Pappas Capital full-time, he worked as a resident physician in surgery at Washington University in St. Louis. He completed his medical degree at the University of North Carolina at Chapel Hill and was involved in research projects in otolaryngology, neurosurgery and medical education, and was elected to Alpha Omega Alpha Honor Society. He also completed his MBA at UNC, earning concentrations in both Healthcare and Entrepreneurship/Venture Capital. He previously completed a research fellowship with Duke University Neurosurgery focusing on development of novel treatments for meningitis and neurologic cancers before medical school. He was a recipient of the Howard Hughes Summer Research Fellowship while at Duke University, with his research focusing on neurobiological basis of drug sensitization.

Drew currently serves as a director for Veralox Therapeutics, as an observer for CuraSen Therapeutics and Glycomine, and on the board of directors of the NC Life Sciences Organization.

Education:
University of North Carolina at Chapel Hill (MD)
Kenan-Flagler Business School at University of North Carolina at Chapel Hill (MBA)
Duke University (BS in Neuroscience)